136 related articles for article (PubMed ID: 8616035)
41. The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia.
Faderl S; Estrov Z; Kantarjian HM; Thomas D; Cortes J; Manshouri T; Chan CC; Hays KJ; Pierce S; Albitar M
Cytokines Cell Mol Ther; 1999 Sep; 5(3):159-63. PubMed ID: 10641574
[TBL] [Abstract][Full Text] [Related]
42. Lack of evidence for mutations or deletions in the CDKN2A/p16 and CDKN2B/p15 genes of Brazilian neuroblastoma patients.
Bassi CL; Martelli L; Cipolotti R; Scrideli CA; Defávery R; Tone LG
Braz J Med Biol Res; 2004 Nov; 37(11):1683-7. PubMed ID: 15517085
[TBL] [Abstract][Full Text] [Related]
43. p16 gene homozygous deletions in acute lymphoblastic leukemia.
Quesnel B; Preudhomme C; Philippe N; Vanrumbeke M; Dervite I; Lai JL; Bauters F; Wattel E; Fenaux P
Blood; 1995 Feb; 85(3):657-63. PubMed ID: 7833469
[TBL] [Abstract][Full Text] [Related]
44. Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer.
Heidenreich B; Heidenreich A; Sesterhenn A; Srivastava S; Moul JW; Sesterhenn IA
Eur Urol; 2000 Oct; 38(4):475-82. PubMed ID: 11025389
[TBL] [Abstract][Full Text] [Related]
45. A novel pre-B acute lymphoblastic leukemia cell line with chromosomal translocation between p16(INK4A)/p15(INK4B) tumor suppressor and immunoglobulin heavy chain genes: TGFbeta/IL-7 inhibitory signaling mechanism.
Urashima M; Hoshi Y; Sugimoto Y; Kaihara C; Matsuzaki M; Chauhan D; Ogata A; Teoh G; DeCaprio JA; Anderson KC
Leukemia; 1996 Oct; 10(10):1576-83. PubMed ID: 8847892
[TBL] [Abstract][Full Text] [Related]
46. Codeletion of p15 and p16 in primary malignant mesothelioma.
Xio S; Li D; Vijg J; Sugarbaker DJ; Corson JM; Fletcher JA
Oncogene; 1995 Aug; 11(3):511-5. PubMed ID: 7630635
[TBL] [Abstract][Full Text] [Related]
47. Alteration of p16 and p15 genes in human uterine tumours.
Nakashima R; Fujita M; Enomoto T; Haba T; Yoshino K; Wada H; Kurachi H; Sasaki M; Wakasa K; Inoue M; Buzard G; Murata Y
Br J Cancer; 1999 May; 80(3-4):458-67. PubMed ID: 10408854
[TBL] [Abstract][Full Text] [Related]
48. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
49. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.
Williamson MP; Elder PA; Shaw ME; Devlin J; Knowles MA
Hum Mol Genet; 1995 Sep; 4(9):1569-77. PubMed ID: 8541841
[TBL] [Abstract][Full Text] [Related]
50. p16 is a major inactivation target in hepatocellular carcinoma.
Jin M; Piao Z; Kim NG; Park C; Shin EC; Park JH; Jung HJ; Kim CG; Kim H
Cancer; 2000 Jul; 89(1):60-8. PubMed ID: 10897001
[TBL] [Abstract][Full Text] [Related]
51. The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance.
Diccianni MB; Chau LS; Batova A; Vu TQ; Yu AL
Cancer Lett; 1996 Jul; 104(2):183-92. PubMed ID: 8665486
[TBL] [Abstract][Full Text] [Related]
52. p16INK4A and p15INK4B gene deletions in primary leukemias.
Haidar MA; Cao XB; Manshouri T; Chan LL; Glassman A; Kantarjian HM; Keating MJ; Beran MS; Albitar M
Blood; 1995 Jul; 86(1):311-5. PubMed ID: 7795238
[TBL] [Abstract][Full Text] [Related]
53. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
[TBL] [Abstract][Full Text] [Related]
54. Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc.
Haviernik P; Schmidt M; Hu X; Wolff L
Oncogene; 2003 Mar; 22(11):1600-10. PubMed ID: 12642863
[TBL] [Abstract][Full Text] [Related]
55. Expression of the tumour suppressor genes p15 and p16 in malignant melanoma.
Robinson WA; Elefanty AG; Hersey P
Melanoma Res; 1996 Aug; 6(4):285-9. PubMed ID: 8873047
[TBL] [Abstract][Full Text] [Related]
56. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma.
Xiao S; Li D; Corson JM; Vijg J; Fletcher JA
Cancer Res; 1995 Jul; 55(14):2968-71. PubMed ID: 7606711
[TBL] [Abstract][Full Text] [Related]
57. Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia.
Yamada Y; Hatta Y; Murata K; Sugawara K; Ikeda S; Mine M; Maeda T; Hirakata Y; Kamihira S; Tsukasaki K; Ogawa S; Hirai H; Koeffler HP; Tomonaga M
J Clin Oncol; 1997 May; 15(5):1778-85. PubMed ID: 9164185
[TBL] [Abstract][Full Text] [Related]
58. Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias.
Hayette S; Thomas X; Bertrand Y; Tigaud I; Callanan M; Thiebaut A; Charrin C; Archimbaud E; Magaud JP; Rimokh R
Leukemia; 1997 Oct; 11(10):1696-9. PubMed ID: 9324291
[TBL] [Abstract][Full Text] [Related]
59. Deletion and differential expression of p16INK4a in mouse lung tumors.
Belinsky SA; Swafford DS; Middleton SK; Kennedy CH; Tesfaigzi J
Carcinogenesis; 1997 Jan; 18(1):115-20. PubMed ID: 9054597
[TBL] [Abstract][Full Text] [Related]
60. Hypermethylation of p15/ink4b/MTS2 gene is differentially implicated among non-Hodgkin's lymphomas.
Martinez-Delgado B; Robledo M; Arranz E; Osorio A; García MJ; Echezarreta G; Rivas C; Benitez J
Leukemia; 1998 Jun; 12(6):937-41. PubMed ID: 9639423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
